Key facts
- OrfonyxBio’s last known valuation is $8.5M (Apr 2025).
- It has raised $6.3M; the latest was Seed Round ($2.6M) in Apr 2025.
- Notable investors include University of Oxford, Oxford Science Enterprises, BioEscalator.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for OrfonyxBio
- ·The full record, as it builds
Funding rounds
No funding rounds for OrfonyxBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About OrfonyxBio
Developer of oligonucleotide drugs designed to activate the expression of specific genes using a novel gene regulatory mechanism. The company specializes in developing an emerging class of genetic medicines that target regulatory elements in untranslated regions of genes.
- Sector
- Healthcare
- HQ
- Oxford, United Kingdom
- Founded
- 2022
- Employees
- 10
- Website
- orfonyx.com/
- Ownership
- Privately Held (backing)
OrfonyxBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in OrfonyxBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on OrfonyxBio in its N-PORT filings yet. We sweep new filings monthly.